CONNECT WITH US
HealthTech

HealthTech

FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival

Medical Xpress logo

Published on

Add as a preferred source on Google
FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Researchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann-Pick type C (NPC) disease, which is a rare and rapidly fatal pediatric neurodegenerative disorder. The drug, known as cyclodextrin (brand name Adrabetadex), extended the survival of participants with NPC in a large, international clinical trial and represents foundational scientific research efforts that began 20 years ago. The drug was approved by the U.S. Food and Drug Administration (FDA) on Nov. 17, 2026.

"Behind every new treatment are years of foundational science that few people see. For a disease as complex and devastating as Niemann-Pick type C, there was no shortcut," said NIH Director Jay Bhattacharya. "It took sustained basic research, careful study of patients over time, and strong partnerships to turn discovery into an approved therapy. NIH is committed to the fundamental science that makes breakthroughs like this possible."

Cyclodextrin directly addresses the issues caused by NPC, namely that a mutation in the NPC1 gene leads to a deficiency of a protein that facilitates regular transport of lipids and cholesterol through cells, leading to abnormal buildup of these substances within cells. Without regular movement of lipids and cholesterol within cells, people with the disease experience progressive neurological decline and premature death.

"I am proud of the role that NIH played in creating the first FDA-approved treatment for infants with NPC, providing new hope to families impacted by this disease," said John Gaitanis, director of NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.